Adam Judge
24Patents
13h-index
26Co-inventors
81Inventor score
Filing activity: Jun 30, 2005 → Oct 25, 2024
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8101741B2 | Modified siRNA molecules and uses thereof | Chemistry; Metallurgy | 140 | Active |
| US8188263B2 | Modified siRNA molecules and uses thereof | Chemistry; Metallurgy | 132 | Active |
| US8236943B2 | Compositions and methods for silencing apolipoprotein B | Emerging Cross-Sectional Technologies | 128 | Active |
| US8513403B2 | Modified siRNA molecules and uses thereof | Chemistry; Metallurgy | 103 | Active |
| US8283333B2 | Lipid formulations for nucleic acid delivery | Emerging Cross-Sectional Technologies | 94 | Active |
| US9074208B2 | Modified siRNA molecules and uses thereof | Chemistry; Metallurgy | 88 | Active |
| US9187748B2 | Compositions and methods for silencing ebola virus gene expression | Chemistry; Metallurgy | 87 | Active |
| US7807815B2 | Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA | Chemistry; Metallurgy | 58 | Expired |
| US7915399B2 | Modified siRNA molecules and uses thereof | Chemistry; Metallurgy | 51 | Active |
| US8227443B2 | Silencing of CSN5 gene expression using interfering RNA | Chemistry; Metallurgy | 27 | Active |
| US8598333B2 | SiRNA silencing of genes expressed in cancer | Emerging Cross-Sectional Technologies | 21 | Active |
| US9878042B2 | Lipid formulations for delivery of therapeutic agents to solid tumors | Emerging Cross-Sectional Technologies | 19 | Active |
| US9006191B2 | Silencing of polo-like kinase expression using interfering RNA | Chemistry; Metallurgy | 17 | Active |
| US8865675B2 | Compositions and methods for silencing apolipoprotein B | Chemistry; Metallurgy | 9 | Active |
| US8716464B2 | Compositions and methods for silencing Ebola virus gene expression | Chemistry; Metallurgy | 9 | Active |
| US11191849B2 | Compositions and methods for delivering messenger RNA | Chemistry; Metallurgy | 4 | Active |
| US11446383B2 | Lipid formulations for delivery of therapeutic agents | Emerging Cross-Sectional Technologies | 3 | Active |
| US11786598B2 | Lipid formulations for delivery of therapeutic agents | Emerging Cross-Sectional Technologies | 3 | Active |
| US11427823B2 | Targeted compositions | Chemistry; Metallurgy | 2 | Active |
| US12016929B2 | Lipid formulations for delivery of therapeutic agents | Emerging Cross-Sectional Technologies | 1 | Active |
| US12251470B2 | Lipid nanoparticle formulations | Chemistry; Metallurgy | 0 | Active |
| US12344675B2 | Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex | Chemistry; Metallurgy | 0 | Active |
| US9222086B2 | Compositions and methods for silencing genes expressed in cancer | Chemistry; Metallurgy | 0 | Active |
| US12043833B2 | Targeted compositions | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.